AMBRX
Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.
AMBRX
Social Links:
Industry:
Biopharma Biotechnology Health Care Life Science Therapeutics
Founded:
2003-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.ambrx.com
Total Employee:
101+
Status:
Active
Contact:
(858)875-2479
Email Addresses:
[email protected]
Total Funding:
347.95 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Google Tag Manager WordPress Domain Not Resolving Wordpress Plugins Sitelinks Search Box
Similar Organizations
Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing novel therapeutics and drug delivery technologies to address chronic inflammatory diseases.
Cognition Therapeutics
Cognition Therapeutics develops new therapeutics to treat patients suffering from Alzheimer’s disease and other neurodegenerative disorders.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
Voyager Therapeutics
Voyager Therapeutics is a gene therapy company developing treatments for fatal and debilitating diseases of the central nervous system
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Suvretta Capital Management
Suvretta Capital Management investment in Private Equity Round - Ambrx
Cormorant Asset Management
Cormorant Asset Management investment in Private Equity Round - Ambrx
HBM Healthcare Investments AG
HBM Healthcare Investments AG investment in Private Equity Round - Ambrx
Fidelity Management and Research Company
Fidelity Management and Research Company investment in Private Equity Round - Ambrx
Invus
Invus investment in Private Equity Round - Ambrx
BlackRock
BlackRock investment in Private Equity Round - Ambrx
Adage Capital Management
Adage Capital Management investment in Private Equity Round - Ambrx
HOPU Investment Management Company
HOPU Investment Management Company investment in Venture Round - Ambrx
Northeast Securities
Northeast Securities investment in Venture Round - Ambrx
Everbright
Everbright investment in Venture Round - Ambrx
Key Employee Changes
| Date | New article |
|---|---|
| 2022-08-16 | Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian |
| 2021-06-30 | Ambrx Appoints Sonja Nelson as Chief Financial Officer |
Official Site Inspections
http://www.ambrx.com Semrush global rank: 2.71 M Semrush visits lastest month: 6.08 K
Unable to get host informations!!!
More informations about "Ambrx" on Search Engine
Ambrx - Ambrx Biopharma Inc. Announces Strategic …
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next …
NEW BRUNSWICK, NJ (January 8, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx Biopharma, Inc., or …See details»
Johnson & Johnson Completes Acquisition of Ambrx
NEW BRUNSWICK, NJ (March 7, 2024) – Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical …See details»
Johnson & Johnson Completes Acquisition of Ambrx
NEW BRUNSWICK, N.J.-- (BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next …
Jan 8, 2024 NEW BRUNSWICK, N.J.-- ( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx …See details»
Ambrx Biopharma Inc. Announces Strategic Reprioritization and …
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic …See details»
Johnson & Johnson Completes Acquisition of Ambrx - Yahoo …
NEW BRUNSWICK, N.J., March 07, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next …
Jan 8, 2024 NEW BRUNSWICK, N.J.-- (BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx …See details»
Strategic Reprioritization and Corporate Update - ir.ambrx.com
2022 Ambrx Biopharma Inc. All rights reserved. Strategic Review Outcome: Overview. Key Objectives. Extend runway from end of year 2023 into 2025. Clear development focus. …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next …
Jan 8, 2024 NEW BRUNSWICK, N.J., January 08, 2024 -- ( BUSINESS WIRE )--Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to …See details»
Ambrx | LinkedIn
About us. Ambrx (Nasdaq: AMAM) is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop next generation …See details»
Johnson & Johnson to Acquire Cancer-Treatment Developer …
Jan 8, 2024 (1 min) Johnson & Johnson said the deal presented an opportunity to “design, develop and commercialize targeted oncology therapeutics.” Photo: Mark …See details»
Ambrx - Crunchbase Company Profile & Funding
About. Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation. Acquired by. Johnson & …See details»
Ambrx Biopharma Inc. Announces Strategic Reprioritization
SAN DIEGO, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ambrx Biopharma Inc., or Ambrx, (NYSE: AMAM), a clinical stage biopharmaceutical company using an expanded genetic …See details»
Johnson & Johnson acquires Ambrx - 2024-01-08 - Crunchbase
Jan 8, 2024 Ambrx Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation. Acquiring …See details»
Ambrx Announces Formation and Members of Scientific Advisory …
Jun 11, 2021 SAN DIEGO– (BUSINESS WIRE)–Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop …See details»
Johnson & Johnson to Acquire Ambrx, Advancing Next …
Jan 8, 2024 NEW BRUNSWICK, N.J. -- (BUSINESS WIRE)-- Johnson & Johnson (NYSE: JNJ) announced today it has entered into a definitive agreement to acquire Ambrx …See details»
Ambrx Announces Sale to Johnson & Johnson - Yahoo Finance
SAN DIEGO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Ambrx Biopharma, Inc., or Ambrx (NASDAQ: AMAM), today announced that it has entered into a definitive agreement …See details»
Ambrx - Funding, Financials, Valuation & Investors - Crunchbase
Funding. Ambrx has raised a total of. $500.9M. in funding over 9 rounds. Their latest funding was raised on May 24, 2023 from a Post-IPO Equity round. Ambrx is registered …See details»